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Abstract
The amount  of biomedical literature is growing rapidly, having nearly doubled the last 
decade. As the literature grows, it is becoming increasingly difficult for curators to keep 
up, as manual curation is a time-consuming process. Past research has indicated that 
computer-assisted curation can speed up this process considerably. 
Our project aims to create a data mining approach using the ClinicalTrials.gov data-
base as our source of data. Using external dictionaries and resources, new data will be 
added to the published trials by expanding on the pre-existing data tags and applying 
various text mining tools. As end product, we will develop a web-based curating tool 
that  allow users to post more advanced queries for clinical trials than the currently ex-
isting interface at clinicaltrials.gov, as well as curate and add/edit manual annotations 
was developed. The system is available at http://invitro.titan.uio.no/clinicaltrials
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Chapter 1 Introduction
Chapter 1 Introduction
This chapter will cover the motivation and problem definition for the thesis, as well as 
providing relevant background information.
1.1 Background and motivation
The amount   of biomedical literature is  growing at  an exponential  pace;  in the last 
decade, MEDLINE has grown at a ~4.7% annual rate. [1]  As the literature grows, it is 
becoming increasingly difficult for curators to keep up as manual curation is a time-con-
suming process. Past research has indicated that computer-assisted curation can speed 
up this process considerably. [2]   
Our project aims to create a data mining approach using the  ClinicalTrials.gov data-
base as our source of data. Using external dictionaries and resources, new data will be 
added to the published trials by expanding on the pre-existing data tags and applying 
text mining to the free text. As end product, we will develop a web-based curating tool 
that will allow users to post more advanced queries for published clinical trials than the 
currently existing interface at clinicaltrials.gov, as well as curate and add/edit manual 
annotations.
While  there  has  been  extensive  focus  on  text  mining  MEDLINE  articles  and 
PubMed abstracts, there has been done far less text mining on clinical trials. There are 
new clinical trials published daily. This makes them an important source for making 
new discoveries about drug/gene/disease relationships. Additionally, trial temporary re-
sults are often accessible before the trial is officially completed, making available infor-
mation that would normally not be published for months or years.   [3] 
This chapter will first provide an introduction to clinical trials, its history and char-
acteristics, as well as the ClinicalTrials.gov database. Then, a summary of related work 
on text mining in biomedical literature will be given, followed by an introduction to lit-
erature curation and the purpose of curation tools. 
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1.2 Clinical trials
A clinical trial is a study conducted to evaluate the efficiency and safety of a new drug 
or treatment method. It is usually performed on a number of volunteers. 
1.2.1 Brief history of Clinical Trials
One of the first clinical trials documented was performed in the eighteenth century. It 
was about the treatment of scurvy (a disease resulting from a lack of vitamin C) aboard 
a ship in the British navy. 12 patients were given 6 kinds of treatment. Two of the pa-
tients who were given citrus fruits (oranges and lemons) showed the most significant re-
covery.
The concept of randomization was first introduced in 1926. The first clinical trial 
that implemented it was done in 1931 by Amberson et al and experimented on a treat-
ment for pulmonary tuberculosis. 24 patients were divided into two groups, where one 
was to receive the treatment of sanocrysin and the other was to receive merely distilled 
water  as  placebo.  Randomization  means  the  patients  were  distributed  randomly  in 
groups. This is important to avoid bias in the results. Blindness was also introduced in 
the same trial (see last section on blind studies). The patients  in this trial were not 
aware if they were actually given the treatment of sanocrysin or in fact just distilled wa-
ter, making it a single-blind study (see below). [4]
1.2.2 Characteristics of Clinical Trials
There are usually certain rules to decide who can and cannot sign up for a clinical trial, 
usually called eligibility criteria. Eligibility criteria often contains an age limit, a certain 
sex, or that the volunteer is diagnosed with a certain disease in a certain stage.
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A clinical trial is normally conducted through several phases, usually three-four. 
In the first phase, side effects and results are considered, and if they're satisfactory, the 
clinical trial will proceed to the next phase. If the clinical trial completes the last phase 
and the results are satisfactory and the side effects are tolerable, it may replace currently 
used drug/treatments. 
One should note that phases are not necessarily conducted consecutively or by 
the same institutions. Each phase uses a subset of tests that were tried and proven suc-
cessful in earlier phases. 
Some clinical trials include control groups. These are groups of participants who 
are given other treatment than the treatment in question, in order to provide something 
to measure the effectiveness of the new treatment against. 
Control groups are usually divided using randomization, i.e. the patients are di-
vided randomly in groups in order to avoid any bias. This can be as simple as flipping a 
coin or using (pseudo)randomly created numbers to delegate the patients into categories.
The control groups may receive no treatment at all, or the treatment that is cur-
rently being used. They are often treated with placebo, which is a treatment that resem-
bles the treatment in observation but doesn't have the same effect (or any at all). 
Usually, neither the patients or the investigators know which group are receiving 
placebo and which isn't in order to give more objective (unbiased) results. This is called 
a double-blind study. In single-blind studies, the patients are unaware whether they re-
ceive placebo or actual treatment while the investigators are informed.  [4] [5]
1.2.3 The clinicaltrials.gov database
ClnicalTrials.gov contains  over 150 000 trials from over 180 countries. Clinical trials 
from the database are primarily available as HTML documents. However, as data min-
ing from the site is fairly common, it also conveniently provides the trials in raw XML 
formats.  These records contain both structured information within uniform tags like 
«drugs» and «investigator», MeSH tags (Medical Subject Headings) as well as unstruc-
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tured information like trial descriptions and other details. Each entry has information 
about the current phase, which countries are involved and eventually what interventions 
were done, e.g. what drugs were being tested. [5]
However,  the  information  in  the  raw  XML formatted  trials  are  not  necessarily 
unique to the one found in the HTML versions. While the latter formats have a full list  
of MeSH terms, including the parent nodes of the leaf nodes from the raw format, the 
XML versions include only the leaves. (This problem is covered in 3.2.4)
Another clinical trial database is the EU Clinical Trials Register 1 / EudraCT 2 data-
base, where all EU countries are obliged to submit information about conducted clinical 
trials. 
1.3 Related work on text mining in biomedical literature
In order to extract terms from the free speech text in clinical trials, both PoS tagging and 
dictionary-based approaches have been used, as well as simply using the terms men-
tioned in the trial description. Trials have also been manually annotated by clinical spe-
cialists in order to categorize them. 
This  has  given  results  ranging from identification  of  previously  unknown gene-
drug-disease relationships to the development of tools improving the usability of or bet-
ter representing the processed information. Here is a summary of various publications 
on text mining on clinical trials. 
In 2011, Korkontzelos et al [6] [7] developed ASCOT, a tool providing a web inter-
face for searching enriched trials. They employed part-of-speech tagging (see 2.1) to ex-
tract terms from free text parts. The main purpose of ASCOT is to simplify the process 
of creating eligibility  criteria when creating new clinical trials.  Typically,  creating a 
clinical trial would include (for inexperienced users) searching for and processing previ-
ous trials in order to list the eligibility criteria. The tool aims to make this step less time-
consuming.
1 https://www.clinicaltrialsregister.eu/
2 https://eudract.ema.europa.eu/
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In 2008, Cao et al  [8] published an article focusing primarily on clinical trials in-
volving cancer vaccines. The aim of the project is to enable users to more easily process 
and understand the information in cancer related trials. As a result, they have developed 
a data mining approach that includes a search interface where users can find information 
about trials exceeding the basic web search at clinicaltrials.gov. 
In 2012, Tasneem et al [9] published an article on  the AACT, an enriched database 
containing additional meta data about the clinical trials. This project had two purposes; 
to improve the usability of the information in the clinicaltrials.gov trials and to find a 
method to classify studies according to clinical specialty.  The trials were classified us-
ing the MeSH root nodes (see 3.2.4) as basis for the specialties. 
Also in 2012, Lu et al [3] pointed out in their publication that a lot of the informa-
tion found in trials are not published until several years after the trial has been conduct-
ed (avg. 5 years), if ever. This is expected as it takes time for trials to be conducted and 
published. Because of this, it is useful to find a way to systematically identify this infor-
mation from the trials even before they are concluded. They hypothesized that clinical-
Trials.gov is rich in information on “how genes affect drug responses in patients with 
specific diseases”, or drug-gene relationships. A text-mining approach to identify rela-
tionships between drugs, genes and diseases was developed using ClinicalTrials.gov as 
their source. 
1.4 Literature curation
Literature curation – or biocuration when applied on biomedical literature – involves 
translating and integrating information relevant to biology into a database or similar re-
source.  The  primary  goals  of  biocuration  are  accurate  representation  of  biomedical 
knowledge, as well as easy access to this data for researchers and scientists. 
1.4.1 Manual curation
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Manual curation implies that the curation process is done by a curator by reading the ab-
stract / article / full text and registering curatable information. Manual curation of bio-
medical literature is both intensive and time-consuming. This coupled with the rate at 
which the literature is growing has created a need for literature curation tools(LCTs) – 
text mining based tools designed to accelerate the curation process. 
1.4.2 Curation tools 
Curation tools allow users to add terms to articles (e.g. a clinical trial or a PubMed arti-
cle) in a more efficient way. In biomedical literature, these are typically genes, species, 
chemicals,  diseases,  etc..  The main purpose behind  LCTs is  to provide users with a 
faster way to annotate the articles than reading though every article and manually enter-
ing every annotation. Additionally, some LCTs processes the literature before making it 
available, extracting and registering annotations before a curator has even opened it. 
Most LCTs works by doing this  automatic annotation through readily available tex-
t-mining tools. This way, the curators do not have to spend time registering the most ob-
vious information. However, no LCTs so far have achieved the precision as expert cura-
tors, and there are sporadic false positives. This introduces the curator with a new task; 
verifying (or invalidating) the automatically registered annotations. Additionally, cura-
tors have to make sure there is no missing information that the algorithms have missed. 
Still, this is in most cases less time-consuming than manually entering every annotation. 
Most LCTs include a tool that enables the users to validate or invalidate these (correct 
for false positives, a result of lacking precision). Eventually, users can look for  annota-
tions that have been overlooked by the algorithms (a result of lacking recall) and use the 
system to register them. 
PubTator, a LCT developed at the National Center for Biotechnology Information, is 
one of the highest rated (highest reported F-measure, highest reduction in curating time) 
biomedical literature curation tools. It provides several types of annotation of PubMed 
articles; document triage, entity annotation and relationship annotation. Users can look 
up abstracts by terms as well, i.e. genes, chemicals and diseases. 
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Illustration 1.1: It features an interface very similar to PubMed in order for  
users, already familiar with the PubMed interface, to avoid having to  
familiarize themselves with a new system. 
PubTator keeps the entire content of PubMed and annotates new articles daily. It em-
ploys  various  text-mining  tools  to  automatically  annotate  genes,  species,  mutations, 
chemicals  and  diseases.  In  document  triage,  users  can  prioritize  which  articles  are 
deemed curatable. Users can then curate the articles and validate/invalidate these anno-
tations, as well as adding their own. As text-mining tools are not 100% correct, there is 
a possibility of false positives (in addition to a lack of recall) in the annotations. As 
such, it  is  useful for users to manually remove certain annotations.  For instance,  as 
shown in Fig. 1.7, in PubMed article PMID 23702042, the abbreviation for the  chemi-
cal Praeruptorin D (PD) has mistakenly been annotated as Parkinson's Disease from this 
sentence: “Praeruptorin D (PD) is one of the major active constituents of Peucedanum 
praeruptorum Dunn (Qianhu)”.
7
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We can confirm that PD is annotated here for Parkinson's Disease by looking up the giv-
en ID in the MEDIC database.  [10] Using the PubTator interface, this can easily be 
fixed simply by deleting the annotation and (possibly) adding the correct chemical an-
notation as shown in Fig. 1.8.
PubTator is acknowledged as one of the best LCTs, and was rated highest and was most 
recommended among all the participants in the interactive text mining track of BioCre-
ative 2012 workshop. [11] It is proven to accelerate the curating process as well as in-
crease the accuracy at which annotation is done. 
8
Illustration 1.2: The PD (Parkinson's Disease) annotation is actually a false positive.
Illustration 1.3: False positive annotation fixed
1.4.2 Curation tools 
Both precision and recall was increased using PubTator, raising the F-measure (the har-
monic mean of precision and recall – see 2.2.3 Evaluating a NER system for details) to 
98% compared to the 92% when annotating manually.  Curating time also decreased 
from an average of 326s to 190s, a 42% increase in efficiency.
MyMiner [12] is another literature curation tool. It provides a simple web interface 
combining PHP, JavaScript and AJAX. It includes triage tasking, classification and an-
notation. The system automatically annotates entities through text-mining tools, specifi-
cally the ABNER[13] tagger for proteins, DNA, RNA, cell lines and cell types and the 
LINNAEUS[14] system for species and organisms. Additionally, the text-mining sys-
tems can be modified to detect user-defined entities if a dictionaries are provided. Auto-
matically annotated entities can be edited by users and false entities can be removed 
completely. It also provides an interface for implying relationships between entities. In 
addition, MyMiner provides the possibility of generating training data for document cat-
egorization. MyMiner was evaluated to manual text annotations generated by unassisted 
or assisted human annotators, showing a decrease in annotation time (up to 90%, aver-
aging on 70%), with no difference in the quality of annotations. 
The NCBO Annotator[15] is another web-based annotator. It is developed by Na-
tional Center for Biomedical Ontology in collaboration with the National Center for In-
tegrative Biomedical Informatics. 
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Illustration 1.4: PubTator annotation performance vs  
manual annotation.
1.4.2 Curation tools 
Several other literature curation tools have been developed that are not meant for 
biomedical text, but rather general text, such as brat (brat rapid annotation tool).
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While some of the information in the trials is easily available, mutations and genes are 
not found in specific locations of the trials, but rather in free text. Extracting these are 
not always as straightforward as extracting already indexed information like drugs and 
MeSH terms. To approach this, we will use various text mining techniques. 
2.1 POS tagging
When processing natural language, one of the most fundamental stages is marking up 
each word into categorizations such as verbs, nouns, adjectives, etc. Additionally, sever-
al words can make up chunks, or phrases. For example, a noun following an adjective 
would make up a noun phrase. A verb leading a a noun or a noun phrase would consti-
tute a verb phase. As a rule (in English), a sentence has to contain a noun phrase fol-
lowed by a verb phase to be valid. The process of categorizing tags into chunks is called 
chunking.
11
Illustration 2.1: A simple example of a POS 
tagged sentence
2.1 POS tagging
While  most  words only have one meaning and in in most cases only one category, 
many words also have two or more different meanings. As such, certain words are am-
biguous, and it is not as straightforward as simply looking at the word itself and assign-
ing  a  category;  the  context  (sentence)  has  to  be  considered  as  well,  increasing  the 
process'  intensity several times.  Consider the sentence “they refuse to permit us the 
refuse permit”. Here “refuse” appears both as a verb and as a part of the noun phrase 
“the refuse permit”, depending on the context. 
Even sentences containing only unambiguous words can be ambiguous as a whole and 
represent different meanings. Consider the sentence “I shot an elephant in pajamas.” In-
tuitively we assume that “I” was wearing pajamas and shot an elephant. Alternatively, 
though, the sentence could also imply that the elephant was wearing pajamas. [16]
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Illustration 2.2: "Refuse" and "permit" appearing with different  
tags, depending on the context. (complete chunking omitted for  
simplicity)
2.1 POS tagging
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Illustration 2.4: "I" shot a pajamas-wearing  
elephant....
Illustration 2.3: "I" shot an elephant while wearing 
pajamas
2.1 POS tagging
Even though the tags are identical, the chunks are different. This is caused by the am-
biguous bindings (or “prepositional phrase attachment ambiguity”); the noun phrase can 
bind with the preceding verb to form a verb phase, or it can bind with the following 
prepositional phrase to form another noun phrase. One approach is to evaluate every 
possible permutation of phrases and find out which ones constitute a sentence (contain-
ing a noun phrase and a verb phrase), but this  is very time-consuming and not feasible 
when dealing with the amount of text we are. As an alternative, it is possible to train 
programs to do this for us, and there exists several kinds of POS taggers. 
2.1.1 Hidden Markov Models
Markov Models are made by and named after Andrey Markov. They work under the as-
sumption that “the future is independent of the past, given the present.” In practice this 
means that if we know the exact state of the present, we can calculate the most probable 
state of the future regardless of the past states, i.e. knowing the past states will not give 
us any more information, as the information is encoded in the present state. Markov 
Models are used for predicting the most probable future outcome in many fields, includ-
ing weather, finance, music, language, etc. We will take a look at how this (or more 
specifically Hidden Markov Models(HMMs)) can be applied specifically in natural lan-
guage processing / text mining to drastically decrease the complexity of POS tagging af-
ter we look at some general examples.  
“For the most reliable weather forecast for tomorrow, look out your window.”
Hidden Markov Models, in contrast to regular Markov Models, contain hidden events 
for each observable step (e.g. a POS tag for each word in a sentence). A very simple ex-
ample of HMM application is the weather example. Here we use a HMM to predict the 
weather each day (hidden events), given only the amount of ice creams that was eaten 
each day (observable states). 
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The complete structure of a HMM is outlined here:
• Q = q1, q2, ..., 1n; a set of N hidden states
• A = a11, a12, ..., an1, ann: a transitional matrix with the probabilities of moving from state i to 
state j
• O = o1, o2, ... oT: a sequence of T observations
• B = bi(ot): emission probabilities, meaning the probabilities of the observation ot given the 
current state i
• q0, qF: start and final state that are not associated with observations
The first step of applying a HMM is to train it on a given training set, i.e. the sequence 
of observable states and the corresponding hidden events. In this example these are rep-
resented by the observed ice cream consumption for each day along with the weather. 
2       H 
2       H 
2       H 
2       H 
3       C 
2       C 
1       H 
3       H 
3       H 
This is an excerpt from what a typical data set would look like. We have here a se-
quence of four consecutive hot days where 2 ice creams were consumed, followed by a 
cold day where 3 ice creams were consumed.  This  is  actually  counter-intuitive and 
“noisy”, as hot days will on average have higher ice cream consumption. The second se-
quence is more representative of the whole data set as the hot days there mostly have 
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higher ice cream consumption. Looking at the weather in these sequences, we can cal-
culate the overall transitional probabilities, i.e. the probability of the weather changing 
from hot to cold or cold to hot and the probability of a sequence ending or starting with 
a cold or hot day. Additionally, by looking at the ice cream consumption, we can calcu-
late  the emission probabilities,  i.e.  the probability  of  hot  or cold weather  given the 
amount of ice creams eaten. We process the data set and calculate the emission and tran-
sitional probabilities using the following formulas:
The transition probabilities  are  assigned simply by looking at  the ratio  between the 
number of times a certain transition from state ti-1 to ti  has occurred in the training set 
and the total number of occurrences of state ti-1. Similarly, the emission probabilities are 
calculated by looking up the ratio between the number of times the hidden event w i has 
occurred along with the state ti and the total number of occurrences of state ti. Some ex-
amples of data after we have processed the complete data set: 
• The probability of starting a sequence of days on a hot day is 76%
• The probability of a hot day following a cold day is 26%
• The probability of cold weather when 3 ice creams are consumed is 14.1%
• The probability of cold weather when 2 ice creams are consumed is 34.1%
• The probability of cold weather when 1 ice cream is consumed is 50.4%
16
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By looking at this information we can intuitively make several assumptions; most days 
in the data set are hot, a day with a given weather is likely followed by a day with the 
same weather, and that the probability of cold weather decreases as the ice cream con-
sumption increases.
We now have a fully trained HMM for predicting the most likely corresponding 
weather for a sequence of days given the amount of ice cream consumption per day. We 
will have a look at how to apply this HMM to unannotated sequences. First we need a 
basic understanding of Bayes Rule: 
P(A, B) = P(A) P(B | A)
inversely, we also get:
P(A, B) = P(B) P(A | B)
therefore:
P(A) P(B | A) = P(B) P(A | B)
->
P(B | A) = P(B) P(A | B) / P(A)
Bayes Rule lets us compute P(B|A) in terms of P(A|B), and makes it possible to make 
the formula for applying the HMM more easily computable. Let's take it from the be-
ginning: the task of the trained HMM is to take an observed sequence of steps (in this 
case, number of consumed ice creams) and determine the most likely corresponding se-
quence of hidden states (weather). 
We then apply Bayes rule to turn the formula into something more tractable; 
17
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Instead of computing the probability of a hidden state given an observation, we compute 
the probability of an observation given a hidden state. Since the denominator is equal 
for every word, we can leave it out of the equation. We now have:
Now we can start estimating the terms. We make two underlying assumptions;
• The probability of a word is only dependent on its part-of-speech tag:
• The probability of a tag is only dependent on the immediately preceding tag (the Markov as-
sumption):
This leaves us with the final formula: 
18
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Now, this can be directly applied either to determine the probability that a given se-
quence of observations will produce a given sequence of hidden states, or it could be 
used to find the most likely sequence of hidden states produced by a given sequence of 
observations.  [17] There exists several approaches for this, but it will not be covered 
here.
2.1.2 Application in biomedical text mining
While the concept of POS tagging and chunking is not directly related to bioinformat-
ics, it can in theory be implemented when looking for entities in free text such as genes 
and mutations using a dictionary-based approach. Since genes and mutations appear as 
nouns or noun phrases, we can use POS tagging / chunking to mark parts of the text that 
should be looked up. In comparison to looking up every possible subset of the text, this 
will be much more efficient. [18]
This assumes that the chunking of a sentence plus looking up the resulting marked 
nouns and noun phrases is not more time-consuming than simply looking up every sub-
set manually. We can make this assumption by comparing the number of look ups that 
are required per string by each operation. Using the NCBI dictionary for human genes / 
proteins [19], there are currently over 46 000 entries. Each of these contain a symbol, a 
description as well as unofficial symbols and alternate descriptions. On average, there 
are 4.89 symbols and/or descriptions for each entry. This means that for each look up 
operation, the string is compared to roughly 220 000 symbols/descriptions. Since we are 
matching every possible subset, we have to perform (n2/2)+n number of look ups per 
string, where n is the number of tokens in the string. When chunking, we perform the 
same number of look ups(using CKY algorithm), yet here we only have the grammar 
rules to consider, which are much more limited than the number of symbols/descrip-
tions. For comparison, the Penn Treebank  [20], which has tagged 7 million words of 
text, contains only 65 unique POS tags. Example:
19
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“ This phase I part of the trial is justified by a possible interaction of the two drugs 
that are substrates of cytochrome P450 CYP3A4 “
This sentence contains a mention of the protein(enzyme) CYP3A4. Processing this sen-
tence manually would require  312 look ups vs just  looking up the nouns and noun 
phrases after POS tagging the sentence. 
2.1.3 Challenges when POS tagging clinical trials
When processing the free text in clinical trials, the section covering the inclusion / ex-
clusion criteria for participation may contain mentions of genes and mutations that are 
not necessarily represented in the brief summary or detailed description of the trial. 
Therefore, the eligibility criteria section should also be processed. However, these sec-
tions are typically structured like bullet points for each criteria. Here's an example ex-
cerpt from the criteria section of a trial 3: 
Inclusion Criteria:
– Age 6 to 75 years old
– Established diagnosis of CF with at least one abnormal G551D-CFTR allele 
– Eligibility for and intent to start treatment with ivacaftor or started treatment with ivacaftor 
within previous 6 months 
POS chunking is done on each sentence independently. These bullet points will be pro-
cessed as sentences, yet they are not structured like conventional sentences, but rather as 
items in a list. This is not optimal as general POS taggers will not be trained on this for-
mat. However, as the full parse tree is not necessarily required, a bottom-up approach 
would be able to fill out the lower part of the parse tree. While this tree would never be 
complete, the bottom-level noun phrases would still be found.
3 http://clinicaltrials.gov/ct2/show/NCT01549314
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2.2 Named entity recognition 
Named entity recognition (NER) is a common approach for automatically annotating 
entities in free text. It combines the problem of recognizing entities in text, assigning 
them to a class (classification) and reducing synonyms to a preferred name (normaliza-
tion). For annotating genes and mutations, we will look at various approaches, including 
several third-party NER systems.
Typical  NER systems apply  rule-based4,  dictionary-based5 and  machine  learning 
based6 methods. Some systems include natural language processing, such as POS tag-
ging / chunking (see  2.1). Dictionary-based approaches simply use a set of names to 
identify entities in the text. These names can then simply be matched exactly against the 
text, which is very precise yet yields a very low recall. Other possibilities are generating 
variants of spelling to compensate for typographical errors in the text. The advantage of 
dictionary-based approaches is the lack of need of a pre-annotated corpora. The down-
side is that context is not taken into consideration. Rule-based approaches use rules to 
separate different classes. Rule-based approaches suffer from a strong trade-off between 
precision and recall. Applying highly specific rules will result in high precision, but  a 
very low recall as most entities will not be detected. Conversely, using very general 
rules will detect most entities but also many false positives, i.e. low precision. Machine 
learning based approaches use a training corpus to perform statistical analysis to deduce 
the most likely context in which an entity would appear. They often implement POS 
tagging / chunking. The downside of machine learning based approaches is the training 
time and the dependency of annotated corpora. [21]
2.2.1 Machine learning
4 e.g.: MutationFinder
5 Basic symbol matching (see 3.2.6)
6 e.g.: BeCAS, Gimli
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To understand how a machine learning based named entity recognizer is developed, a 
basic introduction to the field is useful. Machine learning is the method of “teaching” an 
algorithm to perform tasks by looking at example sets of data. This way, the algorithm 
does not have to be explicitly programmed to solve the problems. 
Machine learning is generally divided into two categories; supervised and unsuper-
vised.  In  supervised learning,  the  training data  is  labeled,  and the desired  output  is 
known. The algorithm will then calculate estimates by processing these data and ap-
proximate a function to determine unseen input in unlabeled data sets. An example of 
supervised learning is the k-NN (k nearest neighbor) algorithm. This algorithm classi-
fies data by looking at the class of the k points which have most similar attributes to the 
target. The learning aspect in k-NN consists of creating classes with attributes that can 
be directly compared with the unlabeled data points in order to measure similarity.
Fig. 2.5 illustrates a k-NN classification. If k is set to 3, the target point will be classi-
fied as a triangle (2 triangle vs 1 square neighbor). If k is set to 5, it will be classified as  
a square  (3 squares vs 2 triangle neighbors).
 In unsupervised learning, no desired output is pre-defined, and the algorithm at-
tempts to  discover structure in the unlabeled data. An example of unsupervised machine 
learning is clustering. As opposed to classification(e.g. K-nn), clustering attempts to cre-
ate classes among data points instead of assigning the data points to pre-defined classes. 
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Illustration 2.5: A simple k-NN 
example
2.2.1 Machine learning
Typically, the training data is divided into a training set and a test set / validation set in 
order to measure the algorithm's performance. This is easily measured as the test set, as 
a part of the training data, is already labeled. As such, no extra effort is required to rate 
the performance of the algorithm.
When training a supervised learning algorithm, training data should be sufficiently 
big in order to minimize potential noise in the data. Additionally, the algorithm should 
not perform the learning phase for too long, as it may adjust to very specific noisy fea-
tures of the training data. This concept is called overfitting, implying it is overly fitted 
specifically to the training data. A clear sign of overfitting is when the algorithm's per-
formance on the training data keeps increasing but decreases for unseen data. This point 
is the optimal time to end the training process. 
Cross-validation is one way to deal with overfitting.  This means dividing the train-
ing data into folds of training sets and test sets (typically one fold assigned as test data 
and the rest as training data). 
A concrete example of a supervised learning task is the classification of electromyo-
graphic (EMG) signals corresponding to various hand motions done in a study by K. 
Glette et al in 2008 [22] demonstrating the potential of evolvable hardware as prosthetic 
controllers. The data is divided into three data-sets (one each day) and contains 40 dif-
ferent signals per motion (10 readings for each of 4 sensors), as well as one classifica-
tion value (label) indicating which of 8 hand motions is being made.
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Illustration 2.6: A simple  
clustering example
2.2.1 Machine learning
We will write a trainable program and apply the k-NN method on the data sets,  
demonstrating  the  use of  cross-validation.  First  the  algorithm processes  the  training 
data, each day divided into separate files formatted with one hand motion for each line. 
Each line includes the label following 40 separate readings. Both label and readings are 
represented with numbers. Specifically, each of the 8 hand motions are represented by 
the numbers 1-8, while readings are represented as decimals ranging from 0-1. First we 
have to find an approach for approximating how similar readings are to each other. 
Since each reading consists of a matrix of values, they can be treated as points in a 40 
dimensional coordinate system. Consequently, we can approximate the similarity by cal-
culating the distance between them. For this, we will use the Euclidean distance, which 
is basically the Pythagorean theorem extended to n dimensions: 
The similarity of two points then can then be calculated from the distance (e.g. d-1, 1-d, 
etc). The training process of the algorithm consists of loading the training data in order 
to later use the “coordinates” as neighbors when classifying unlabeled data. When given 
unlabeled input, the k-NN algorithm assigns the point to the class which is most promi-
nent among its k neighbors, i.e. the k most similar points from the training data. 
To evaluate our k-NN algorithm, our training data is divided into a training set and a 
validation set. In the simplest case, this is done simply by splitting the original set arbi-
trarily. However, the evaluation results obtained this way tends to be affected by how 
the data is split. To reduce this bias, we will use cross-validation. This means using dif-
ferent “folds” as test set. In our case, we will divide the training set into 5 folds, and use 
each fold as a test set once. Results:
Data set Accuracy Standard dev.
Day 1 95.8% 8.4%
Day 2 92.0% 11.2%
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Day 3 96.0% 9.7%
Day 1-3 93.9% 7.2%
Here we are using the same sets for training and evaluation (including cross-valida-
tion). The table shows the accuracy of the algorithm as well as the standard deviation of  
the results from the cross-validation. In this problem, the k-NN is able to score relative-
ly high. Typically, less sophisticated algorithms such as k-NN will have a lower score 
on more complicated training data. 
2.2.2 Training a named entity recognizer
Being a machine learning based approach, NER systems are trained by processing a 
pre-annotated corpus, or training set. As an example, let's look at the methods for train-
ing a simple NER with a few classes; names, locations and organizations. Creating a 
training set for this NER would mean tagging a huge amount of free text with occur-
rences of these classes. How these occurrences are tagged are not important, as long as 
the learning algorithm knows how to make them out, i.e. they should not be ambiguous 
or contain characters that can be mistaken as part of the text itself. Let's look at an ex-
cerpt from a typical training set. Original text:
“The fate of Lehman Brothers, the beleaguered investment bank, hung in the bal-
ance on Sunday as Federal Reserve officials and the leaders of major financial institu-
tions continued to gather in emergency meetings trying to complete a plan to rescue the  
stricken bank.  Several possible plans emerged from the talks, held at the Federal Re-
serve Bank of New York and led by Timothy R. Geithner, the president of the New York  
Fed, and Treasury Secretary Henry M. Paulson Jr. ” 7
And then after the original text has been annotated for the purpose of training our sim-
ple three-class NER:
7 Example from the Stanford NER (http://nlp.stanford.edu/software/CRF-NER.shtml)
25
2.2.2 Training a named entity recognizer
“The/O fate/O of/O Lehman/ORGANIZATION Brothers/ORGANIZATION ,/O the/O  
beleaguered/O investment/O bank/O ,/O hung/O in/O the/O balance/O on/O Sunday/O 
as/O Federal/ORGANIZATION Reserve/ORGANIZATION officials/O and/O the/O  
leaders/O of/O major/O financial/O institutions/O continued/O to/O gather/O in/O 
emergency/O meetings/O trying/O to/O complete/O a/O plan/O to/O rescue/O the/O  
stricken/O bank/O ./O 
Several/O possible/O plans/O emerged/O from/O the/O talks/O ,/O held/O at/O  
the/O Federal/ORGANIZATION Reserve/ORGANIZATION Bank/ORGANIZATION 
of/ORGANIZATION New/ORGANIZATION York/ORGANIZATION and/O led/O by/O  
Timothy/PERSON R./PERSON Geithner/PERSON ,/O the/O president/O of/O the/O  
New/ORGANIZATION York/ORGANIZATION Fed/ORGANIZATION ,/O and/O Trea-
sury/ORGANIZATION Secretary/O Henry/PERSON M./PERSON Paulson/PERSON 
Jr./PERSON ./O ”
The format of the training set is straightforward and intuitive; each word, or token, is 
followed by a slash and then either a given class or a 0 if no class is assigned. Another  
typical tagging system is to encapsulate every entity in XML tags, e.g. “<PER>Henry 
M. Paulson Jr.</PER>”. This eliminates the need for a tag for every class-less word and 
makes it more clear where an entity begins and ends. 
Given this  information,  the NER calculates estimations that  will  determine what 
words are tagged when it is later run on un-annotated text. When learning from the 
training set, our tagger will consider the position of the class, i.e. preceding and suc-
ceeding words/classes (N-grams), and of course the word itself. More advanced NER 
systems will use several other features such as POS tagging, conjunctions(disambigua-
tion of candidates containing “and/or”) and many more. 
Naturally, annotating such corpora of sufficient size is both a time-consuming and 
expensive effort, making them scarce and valuable. Research has been made on the pos-
sibility of combining different corpora with only partially semantic overlap as a single 
training set to make up for this. [23]
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2.2.3 Evaluating a NER system
To measure the performance of a named entity recognition system, the traditional F-s-
core (or F-measure)  system is usually used. This score evaluates the recall and preci-
sion of the system. The recall is the number of correct results divided by the number of 
correct results that should have been found, while precision is the number of correct re-
sults divided on the number of total results. In short, recall reflects how many of the re-
sults the system manages to pick up, while precision is basically a measurement of noise 
in the results. 
The F-score itself ranges from 0 to 1 (often translated into percent) and is calculated 
by as the harmonic mean of precision and recall. The harmonic mean of two numbers is 
calculated simply as the product of the numbers divided by the sum of the numbers, 
multiplied by two. 
 Some examples of evaluation of NER systems:
System Precision Recall F-Measure
Gimli NER 90.22% 84.32% 87.17%
BANNER 85.09% 79.06% 81.96%
ABNER 83.21% 73.94% 78.30%
LingPipe 60.34% 70.32% 64.95%
The F-score is not used only on NER systems, but is applied in general in statistics to 
measure accuracy.
2.2.4 NER in the biomedical domain
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The recognition of biological concepts in free text is problematic due to several factors. 
There are no naming conventions for gene / protein names, which makes it difficult to 
establish general rules when looking for them. Additionally, there are typically several 
different names used for each gene / protein, including alternate descriptions which may 
consist of up to several words. In many of these descriptions, it  is not always clear 
where the gene / protein name starts and ends, such as 'cellular retinoic acid binding 
protein 1'. According to the BioCreative corpus of expert-tagged gene names, 53% of all 
names consists of more than one token, so this problem is not unusual. Another promi-
nent problem when looking for genes/proteins are names identical to common acronyms 
or words. MRI, which is an alternative symbol for the gene C7orf49, is identical to the 
acronym for magnetic resonance imaging. CSF, one of the alternative symbols for both 
CSF2 and LAMC2 gene, is identical to the acronym for cerebral spinal fluid. Addition-
ally, there are gene symbols which are outright idiotic, such as STOP, IF, FISH.  [21]
While many NER packages are designed to classify several entities (genes/proteins, 
mutations diseases or drugs), most packages are class specific, meaning they are de-
signed only to find one particular type of entity. Unlike gene / protein names, certain 
types of mutation names are named more systematically and can more easily be re-
trieved using simple regular expressions. Specifically, point mutations are named in the 
following format: a letter indicating the amino acid that is replaced by the mutation, fol-
lowed by a number indicating the position of the mutation, followed by a letter indicat-
ing  the  amino  acid  that  has  replaced  the  original.  For  example,  the  point  mutation 
G551D would indicate “a  glycine[G]-to-aspartic acid[D] missense mutation at codon 
551”. 
There has been significant progress recent years in biomedical named entity recog-
nition(BNER).  Several  freely available  BNER systems are  available,  such as  BAN-
NER[24], ABNER[13], LingPipe and of course BeCAS and Gimli which have been 
evaluated on clinical trials in this thesis and will be covered at the end of the chapter.
2.2.5 Challenges specific to clinical trials 
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As with POS tagging, the bullet point format of the criteria section is not ideal for NER 
packages as they are trained on typical sentences. This may cause a lowered precision 
and recall. 
2.2.6 GNAT
One of the NER packages we will evaluate on clinical trials is GNAT8, an open source 
Java library developed by Hakenberg et al. In addition to named entity recognition, the 
package provides normalization of gene and protein mentions. GNAT features a web 
service that can be used directly through a browser by providing arguments in the URL. 
Example:
h  ttp://bergman.smith.man.ac.uk:8081/?text=human%20p53%20protein&task=gnorm  
In this example, the task would be normalization of the string “human p53 protein”. 
However, this web service doesn't really seem to be a fan of running, which obviously 
will  cause problems.  As of  November 2013,  the  web interface seems to have  been 
moved  to  http://cbioc.eas.asu.edu/gnat/start.html,  where  posting  a  query  still  returns 
nothing but an error message. GNAT also provides a programmatic / command-line ap-
proach. Unfortunately, this approach also seems to be dependent on the same server as 
the web service.  [25]
2.2.7 Gimli
8 http://gnat.sourceforge.net 
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Gimli9 is another open source Java library for named entity recognition. It is developed 
by David Campos et al. This package is highly customizable and includes the possibility 
of training customized models. These models can then be combined or run individually 
when processing text. Gimli is also dependent on a remote web service, but fortunately 
it tends to stay running. [26]
2.2.8 BeCAS
BeCAS is another web-based service for recognizing biomedical concepts. It is devel-
oped by a team consisting largely of the same developers / researchers as the Gimli 
team. However, while Gimli seems to have a focus on customizable training models, 
BeCAS is more focused on addressing multiple concept types and using external data-
bases. [27]
9 https://github.com/bioinformatics-ua/gimli
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Chapter 3 Enriched Trial Database
3.1 Design
To store the information about the trials, a back-end MySQL database was created. The 
database is divided into separate tables with a main table containing the basic informa-
tion and additional tables for each category of extracted information. 
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3.1. Illustration: ER diagram of the enriched trial database
3.1 Design
3.1.1 Main table
Trials are indexed with their trial IDs as their primary keys. In addition, there are col-
umns for the trial's phase, status (completed, recruiting, etc...), type (interventional, ob-
servational, etc...), their official title, their source (what group, university or corporation 
that initiated the trial) and the date they were added to clinicaltrials.gov.
3.1.2 Locations
A separate table exists for the trials' locations, i.e. the countries involved in the trials. 
The reason that a separate table exists for this and that it's not included in the main table 
is that there are potentially several countries referencing one trial (one to many relation-
ships).
3.1.3 Drugs
Information about extracted drugs have a foreign key referencing their trial's ID, a col-
umn containing the name of the drug and a phrase representing the original pre noise fil-
tering context that the drug was extracted from (more details on the implementation sec-
tion). Lastly, it contains a column indicating whether there is a match for the drug entry 
in  the DGIdb (Drug Gene Interaction database)  [28],  which is  used for  looking up 
search results in the curator tool.
3.1.4 MeSH terms
In addition to the trial ID foreign key, the table representing MeSH terms consists of a  
column for the MeSH term itself, as well as a column indicating its source (whether it 
was originally extracted from the trial or if it is a parent of a extracted term – more de-
tails in the implementation section). 
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3.1.5 Abbreviations
This table is rather self-explanatory, containing a column for the abbreviation and the 
phrase it abbreviates. This table was included to assist in filtering out noise/false posi-
tives when identifying gene symbols.
3.1.6 Genes
Genes are represented with entreZ IDs[29], gene symbols and gene names - both official 
and alternative. As a result, the gene table has the largest number of columns in the data-
base. In addition to columns representing these fields, a gene entry also contains col-
umns for the original match phrase, for indicating whether the entry has been normal-
ized as well as possible comments and validation markers from the CT curator(chapter 
4).
3.1.7 Mutations
The mutation table simply contains a single column containing the mutation phrase in 
addition to the foreign key.
3.1.8 Additional tables
In addition to these tables, there are tables used for known general drug names, specifi-
cally drugs listed in the DGIdb database. This information is used by the CT curator to 
list potential genes in the same trial that are known to have interactions with the given 
drug. Additionally, there is a table listing possible relations between genes and muta-
tions being mentioned in the same trials. Lastly, another table is used to keep track of 
which trials have already been processed when updating the database with new trials 
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from clinicaltrials.gov (see 3.2.7 on maintenance). These tables are not included in the 
ER diagram. Tables for the evaluated but not implemented gene indexing methods are 
not included either.
3.2 Implementation
This sub-chapter will cover the process of how the database was put together. Various 
problems encountered during implementation and decisions made will also be covered 
here.
3.2.1 Trial files / main table
ClinicalTrials.gov provides a crawler service that allows users to systematically down-
load every submitted trial.  [30] Using the LWP::Simple Perl library [31], a script iter-
ates through the trials and downloads them. 
Trials are published in two formats; an XML format and an HTML format. Primari-
ly we will be working with the XML files, but as certain parts are not formatted suit-
ably, the HTML files are also downloaded. 
As each trial is successfully downloaded, its trial ID is inserted into the main table. 
Another script later processes the trials and extracts the basic information (sources, offi-
cial title etc.) to complete the table.
3.2.2 Countries / locations
Separate tables were created to store the involved countries in each trial as well as 
the exact given address. Here is a summary of the most involved countries:
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Occurrences Country
74779 United States
12226 Canada
11299 Germany
10119 France
8687 United Kingdom
6620 Italy
6078 Spain
5283 Netherlands
5091 Belgium
4920 Republic of Korea
There is a clear dominance of US-involved clinical trials, although this is partly attribut-
able to ClinicalTrials.gov being an American site. The US is followed by Canada which 
is involved in merely 1/6 of the number of trials. After Canada, mostly European coun-
tries make the top 10.
More specifically, we can look at the exact address of the involved parties. This 
gives us an overview of the participation of the individual parties, not just countries in 
general. This list topped by a  good margin by 77030, Houston, Texas, USA, which is 
the address of The University of Texas Health Science Center at Houston. 5261 trials 
registers involvement with this address.
Occurrences Address
5261 77030, Houston, Texas, USA
(The  University  of  Texas  Health  Science 
Center at Houston)
3297 20892, Bethesda, Maryland, United States
(National Institutes of Health Clinical Center)
2801 02115, Boston, Massachusetts, United States
(Northeastern University)
2668 19104,  Philadelphia,  Pennsylvania,  United 
States
(University of Pennsylvania)
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Occurrences Address
2375 55905, Rochester, Minnesota, United States
(Mayo Clinic in Rochester)
2374 27710, Durham, North Carolina, United States
(Duke University Medical Center)
2343 02114, Boston, Massachusetts, United States
(Massachusetts General Hospital)
2203 10021, New York, New York, United States
(Memorial Sloan-Kettering Cancer Center )
2114 78229, San Antonio, Texas, United States
(University of Texas Health Science Center at 
San Antonio)
2098 10032, New York, New York, United States
(Columbia University Medical Center)
3.2.3 Abbreviations
Locating abbreviations was done using a Python script written by Vincent Van Asch 
[32].  The script is simply run given the path to the trial folder and recursively processes 
all trials.
3.2.4 Drug extraction and noise reduction
The XML files contain fields specifically for drugs used in the trial. They are found 
within “<intervention>” tags where sub-tag “<intervention_type>” is listed as a drug. 
The drug name itself is then found in the trailing sub-tag “<intervention_name>”. Ex-
tracting these are straightforward enough and is done separately by a perl script.
However, there doesn't seem to be any rules or standards as to how drug names are 
submitted. This presents a problem, as the drug entries are in many cases accompanied 
by dosage size, intended time interval between doses or other (in our case) superfluous 
information. Drug entries may even contain whole sentences describing the administra-
tion of the drug.  
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Two or more drugs may also be listed as one entry contrary to being listed in sepa-
rate tags. These are divided in arbitrary ways, either by natural language (“and”, ”or”, 
“combined with”, etc...) or symbols (e.g.: “/”, “+”). 
As shown in Fig. 3.2, there is a lot of noise in the original entries. Additionally, “place-
bo” is listed as a drug in several trials, and should be excluded.
To  deal with this, the entries are run through a Python filtering script that reduces 
noise and excludes certain entries. This is done using regular expressions, stop lists and 
Python string editing functions. A full overview of the drug filtering process is outlined 
here: 
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Illustration 3.2: Samples of original drug entries
3.2.4 Drug extraction and noise reduction
– Drugs have all non-ASCII characters (drugs are at times trailed by ® and/or ) removed as 
they aren't necessary for our project's purpose and they tend to  cause problems with the 
MySQL database.
–  The entries are split on possible separator words and symbols to separate any multiple en-
tries. 
– A stop-list is used to filter out unnecessary information (including all “placebo” mentions).
–  Another stop-list is used to filter  out dosage information; all  measurement units are re-
moved. Likewise, all numbers leading a measurement unit are removed.
– Entries are looked up against WordNet [33], a lexical database for English. All words that 
are common (not drug names) are excluded.
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Illustration 3.3: Samples of filtered drug entries
3.2.4 Drug extraction and noise reduction
Fig. 3.3 shows the samples from 3.2 after being run through an early version of the fil-
tering script. The rows have been affected in several ways. For instance, the multiple-
drug containing entry from NCT01625871 has been divided into two separate ones, and 
the dosage information (“tablets”) has been filtered out. The mp-214 entries are also 
stripped of dosage information. Both placebo entries have been left out entirely. Howev-
er, the NCT01625286 entries still contain noise as there is residue from the dosage in-
formation that has not been completely filtered out.
After all entries have been filtered, 131133 out of 150804 trials contained one or 
more drug entries10. These are the most common entries:
Drug name Total occurrences
Cyclophosphamide 1639
Cisplatin 1478
Paclitaxel 1284
Carboplatin 1243
Gemcitabine 1218
Docetaxel 1134
Dexamethasone 952
Bevacizumab 840
Doxorubicin 811
Etoposide 792
3.2.5 MeSH terms extraction and the MeSH tree
MeSH  (Medical Subject Header) is a vocabulary used for indexing MEDLINE articles. 
The vocabulary is  constructed as a tree with 16 top level categories, who represent very 
general subjects, e.g. diseases, drugs/chemicals, organisms, etc. Each category can be 
divided into several, more specific nodes. These are then divided into other, even more 
specific subjects, down to as much as twelve levels. 
10  As of October, 2013
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As in drug extraction, MeSH terms are easily extracted as they are located within pre-
defined  tags.  Clinical  trials  from clinicaltrials.gov  are  already  indexed  with  MeSH 
terms. However, contrary to the HTML files, the XML files do not represent the full set  
of the MeSH terms, only the leaf nodes. To include the rest of the branch, we look up 
the MeSH tree and recursively find the terms' parent nodes. A MeSH term may also be a 
child  of  several  parent  terms.  For  example,  'Leukemia,  Lymphoid'  is  a  child  of 
'Leukemia' as well as two different nodes representing 'Lymphoprofilerative Disorders' 
(also ambiguous entries), where one of these is a child of 'Lymphatic Diseases' and the 
other is a child of 'Immunoproliferative Disorders'. This shows that a single MeSH term 
can branch up to several subcategories and root nodes. When dealing with these ambi-
guities, all parent branches are included.
Here is a summary of the most common MeSH terms, both entries extracted directly 
from the XML files and entries from the extended MeSH tree:
MeSH_term XML Extended Total
Neoplasms 5881 33482 39363
Pathological 
Conditions,  Signs 
and Symptoms
0 33825 33825
Organic Chemicals 0 26595 26595
Cardiovascular 
Diseases
1948 18920 20868
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Illustration 3.4: An example of the MeSH tree using Congenital  
Abnormalities as root node
3.2.5 MeSH terms extraction and the MeSH tree
MeSH_term XML Extended Total
Heterocyclic 
Compounds
0 20234 20234
Nervous  System 
Diseases
0 18020 18202
Immune  System 
Diseases
45 17909 17954
Neoplasms  by 
Histologic Type
7 17327 17334
Pathologic 
Processes
8 17325 17333
3.2.6 Genes
For annotating genes in the trials, several different approaches were tested and evaluat-
ed. A basic dictionary-based approach was programmed that matches text against the 
NCBI dictionary of human genes. Additionally,  three third-party NER systems were 
tested; GNAT,  BeCAS and Gimli. 
To evaluate  the various approaches,  a  set  consisting of  100 trials  was selected, 
where each trial had one or more genes found by the initial dictionary-based approach. 
The trials were then manually curated, and the results were compared against the auto-
matic annotation.
The dictionary-based approach works by simply loading the 46315 different genes 
into a Perl hash, including all alternative symbols, descriptions and alternative descrip-
tions. The script then matches every sentence for partial or complete matches of gene 
names,  and  each  word  for  matches  against  symbols.  Matches  are  then  normalized 
against the gene ID, main symbol and main description of the gene.  The initial idea of 
using POS tagging to avoid redundant lookups (i.e. only look up nouns and noun phras-
es – see 2.1.2) was discarded as the potential time saved in runtime was not worth the 
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development time that would go into finding  and implementing a suitable (or program-
ming a new, domain-specific) POS tagger. As this approach does not consider context, a 
very low precision level was achieved.
Recall 84.47%
Precision 54.65%
F-score 66.37%
GNAT was dependent on a remote web service which consistently seemed to go offline. 
Even when results were produced, they were erratic. Albeit these poor results were most 
likely attributable to poor configuration on my part, after consistent failure with GNAT, 
the idea of using the system was discarded in order to put time into trying other tools. 
As such, no test data was produced for GNAT.
Gimli NER requires pre-processing before doing the actual annotation. First, the text 
has to be formatted into one sentence per line. Gimli then converts this file into a so-
called corpus. This is done using the Genia Dependency Parser (gdep). Formatted cor-
pora are formatted with a unique identifier separated with a whitespace from the sen-
tence, like this (for each sentence):
“NCT00326339 R406 is metabolized by CYP3A4, and ketoconazole increases the R406 
AUC of a dose of R788 by approximately 2 fold.”
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Illustration 3.5: Gimli workflow, from bioinformatics.ua.pt/support/gimli/doc/
3.2.6 Genes
Gimli then uses one or several models to annotate the corpus. The system can train 
models,  and there  are  trained models  available.  In  our  case,  we are  using  a  model 
trained on BC2, using forward parsing.  When Gimli is done annotating, the output of 
our example sentence will look like this:
“NCT00326339|18 24|CYP3A4”
where 18 and 24 are the positions of the first and last char of the entity. For normaliza-
tion, the match phrases were mapped against the gene symbols/descriptions using a part 
of the code for the basic dictionary-based approach. 
Gimli reports an F-score of 87,54%  on BioCreative test data and 73,05% on JNLP-
BA test data. (This gap between BC2 and JNLPBA performance  is typical.  [34]) On 
clinical trials, this is how Gimli performed:
Recall 83.71%
Precision 75.42%
F-score 79.35%
Clearly Gimli has an advantage over the basic symbol matching method. While the F-S-
core does not compete with the results from the BC2 test sets, it exceeds the perfor-
mance on JNLPBA. 
BeCAS is easily implemented through a python package or a script, and in contrast 
to Gimli does not require the data to be converted prior to annotation or pre-trained 
models. Rather, the data is submitted to a web API and processed remotely. For normal-
ization, BeCAS returns a UniProt ID along with the annotated concept. This UniProt 
can be converted to a Gene ID, which can then be used to retrieve the gene's symbols 
and descriptions. However, using this method to normalize gave worse results than us-
ing the same method that was used on the Gimli results. This is how BeCAS performed 
on the test data: 
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Recall 77.65%
Precision 71.43%
F-score 74.41%
 Naturally, as Gimli excels both in recall and precision, it was chosen for use in the au-
tomated annotation.
3.2.7 Mutations
To extract mutations from the trials, a rule-based system named MutationFinder  [35] 
was applied. It is available in Python, Perl and Java. We have included the Python ver-
sion in our pipeline as it is easily downloaded and installed as a separate module that 
can be addressed programmatically. 
MutationFinder only extracts point mutations. Extending the approach to other types 
of mutations would introduce a new problem; as point mutations are named based on 
rules (see 2.2.1), they are easily detected in free text. However, other types of mutations 
are more ambiguous and there aren't many readily available open-source packages deal-
ing with them.
The point mutations detected by MutationFinder are stored in the database. Another 
script then attempts to couple the mutations to genes that are also detected in the same 
trials. This is done by looking up the sequence of amino acids of the gene candidates. A 
potential relation between a gene an the mutation is then easily detected by checking the 
given amino acid at the given position (codon) in the mutation name. If the amino acid 
in the gene sequence is the same as the original amino acid in the mutation name, the 
mutation may be corresponding to the gene. Let's look at an example; we have an occur-
rence of the mutation V600E and the BRAF gene in the same trial11. Here is an outline 
of the process for determining gene-mutation relationship: First we look up the amino 
acid sequence for the BRAF gene:
11 E.g.: NCT01827384 
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MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQRE-
QQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMR-
GLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNY-
DQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNID-
DLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGK-
WHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSI-
IHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGR-
GYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH
We then locate the amino acid at the position given in the mutation's name: the 600 th 
amino acid is valine, which corresponds with the mutation. Thus, the V600E mutation - 
or every V600* mutation - can potentially be related to the BRAF gene. Information 
representing this relationship is stored in a junction table between the gene table and the 
mutation table.
After all mutations were matched again potential genes, barely half of the mutations 
matched up against a gene; only 712 out of 1298 mutations had a potential gene candi-
date in the same trial. This could be caused by poor gene annotation (a lack of recall re-
sulting in the mutation's gene not being detected), and/or poor mutation annotation (a 
lack of precision resulting in a false positive mutation match).
Total number of mutations 1298
Mutations  matched against  one  or 
more genes
712
Mutations without matches 586
% of matched mutations 54.9%
A total of 461 different unique mutations were registered, the most prominent being the 
V600E mutation.  Other frequent mutations are summarized here:
Mutation Occurrences
V600E 65
L858R 46
T315I 43
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Mutation Occurrences
C282Y 35
M184V 32
T790M 29
K65R 27
G20210A 25
P13K 23
H63D 21
Additionally, we can see from combining the gene and mutation tables that the majority 
of V600E annotations (77%) are found in trials where a mention of the BRAF gene is 
also found. The BRAF gene is found in a total of 228 unique trials, meaning 22% of 
BRAF-related trials also include the mutation. This information reflects the fact that the 
V600E mutation in the BRAF gene is a common mutation known to cause certain types 
of cancer and is being researched a lot. 
Occurrences Gene
50 BRAF
6 ALB
1 PMEL
Among other genes that can contain a V600E mutation, albumin also occasionally ap-
pear in the same trials as the mutation.
3.2.8 Maintenance
Naturally, an important part is to keep the database up-to-date with newly published 
clinical trials. In order to ensure that the most recent clinical trials are available and an-
notated, a script will download every new trial, process them and store the results. The 
curator tool is then automatically updated to include these trials. 
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As the results from certain scripts are dependent on the results of other scripts, the 
maintenance makes sure the scripts are run in the correct order. They are run in the fol-
lowing order:
1. The XML files are downloaded
2. Basic information is extracted from the trials (title, phase, source, status, date and study type 
(observational vs interventional) ).
3. Raw/free text is extracted from the XML files, i.e. the brief summary, detailed description 
and eligibility criteria sections.
4. Countries and locations/addresses are extracted
5. Drugs are extracted from the trials
6. Drug entries are filtered and matched against the DGIdb table
7. MeSH entries are extracted
8. MeSH trials are looked up against the MeSH tree, extracting parent terms and adding them 
to the database
9. Mutations are extracted using MutationFinder
10. Abbreviations are extracted and loaded
11. NER packages for gene mention detection are run
12. Gene entries are normalized, i.e. entries are matched against the NCBI gene name list and 
associated with a gene symbol 
13. Potential links between detected mutations and genes are found
This script should be run at least on a weekly basis to ensure the database is current.  
Typical running time if run weekly is roughly 20-40 minutes. 
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Chapter 4 CT curator
This chapter will cover the functions of the CT curator web tool and how it is imple-
mented. The CT curator is available on http://invitro.titan.uio.no/clinicaltrials
4.1 Posting queries
The CT curator provides a user interface for looking up the information extracted from 
the  trials.  It  is  done  simply  by  choosing  a  class  of  items  from  a  drop-down  list 
(gene/protein, mutation, drug or MeSH term) and then typing the search term.
A search suggestion feature will  recommend entries from the database if  two or 
more characters are entered. For example, by selecting genes as our class and entering 
the phrase “CYP3A”, a list of the genes in the CYP3A cluster will appear as long as  
they have been found in one or more trials.
 Similarly, typing “cytochrome p450, family 3, subfamily a” will return the same list, 
only represented as gene descriptions instead of symbols. Terms can either be selected 
from this list or written manually. 
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When the query is posted, a list is returned with trials containing the search term. These 
trials are sorted chronologically and a superficial representation is given,  containing tri-
al ID, phase, date received by clinicaltrials.gov, their official title as well as a flag for 
each nation involved. Results can then be filtered by country and phase simply by se-
lecting the values from two drop-down lists at the top of the results. 
Following the “more details...” link will open a more detailed representation of the se-
lected trial. This view also includes the exact locations of the involved parties, brief 
summary, detailed description, eligibility criteria section as well as a list of annotations. 
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Each class of annotations (genes, drugs, mutations and MeSH terms) are represented in 
a sidebar as lists of items. Genes and mutations are also highlighted in the free text. 
Some classes includes a tool  tip  with more details.  For example,  when highlighting 
genes, a tool tip will appear including the following details:
– The original match phrase from the free text
– The official symbol (if found)
– The official gene description (if found)
– A link to the NCBI page on this gene
Drugs are marked in blue. Highlighting them will display a tool tip including the fol-
lowing details:
– The original phrase found in the clinical trial XML file
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– The drug entry after being filtered for superfluous information (see 3.2.3). These entries are 
used when looking up search terms.
– Information from the DGIdb about known interactions with protein/genes 
Mutations include the information obtained from the process in 3.2.6. If any potential 
genes appear in the same trial, these are listed in the mutation's tool tip. 
MeSH terms are listed in bright red and dark red; a bright red background indicates 
that the item was found in the original XML file. A dark red background indicates that 
this item is a parent MeSH term extracted from one of the original terms (see 3.2.4).
4.3 Interacting with trials and annotations
Comments can be added by users through the ct curator, either to trials as a whole, or 
individual annotations. While viewing the detailed version of a trial, comments can be 
added simply by typing the comments in the “user comments” box beneath the trial 
title / summary. Comments will then be visible for other users, both in the detailed view 
and when the trial is a part of a set of returned search results. 
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Additionally, gene annotations can be marked as correct or incorrect (“undecided” by 
default). Annotations that are false can also be removed completely. This can be done by 
opening a gene tool tip and clicking the corresponding link. Trials as a whole can also 
be marked curatable by marking the check box at the top of the view. A check mark will 
then appear next to the trial when it is part of a set of returned search results. Lastly, 
users can add gene/protein and drug annotations that are overlooked by the system. 
MeSH terms are not editable for the simple reason that they are fetched from an unam-
biguous list which leaves no possibility for false positives. 
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Chapter 5 Discussion
Using various text mining tools, I have developed a system for assisted curation of clini-
cal trials. These annotations are accessible through a web interface where they can be 
edited or deleted. Creating manual annotations is also possible. 
There is clearly room for improvement in the automatic annotation. While there are 
no concrete numbers available to measure the performance of the annotation of muta-
tions (i.e. F-score), by looking at the number of found mutations that have no corre-
sponding genes in the same trial, one can assume that there is a lack of precision. It 
would be interesting to evaluate additional pattern-based approaches for detecting muta-
tions. 
While the performance of the annotation of genes was acceptable, it would be inter-
esting to see if Gimli could be tweaked to improve precision and recall, e.g. by testing 
different models in addition to the default BC2 trained model. The algorithm for nor-
malizing genes could also be improved. 
In retrospect, more specific methods for selecting the evaluation set may have been 
more  appropriate,  e.g.  focusing  on  cancer-related  trials  using  MeSH  terms  (“Neo-
plasms”, etc.) as a filter. Additionally, the dictionary-approach was riddled with false 
positives, resulting in trials with no actual genes being included in the set.
The CT curator itself could also benefit from some improvements. While it provides 
an interface for editing existing annotations, it does not support definition of associa-
tions/relations  between  bio-concepts.  Particularly  pharmacogenomic  relationships 
would be useful. Also, while it is functional, it is very primitive and written in hand cod-
ed PHP and JavaScript. As was suggested, using a web framework  could make the CT 
curator more user friendly and efficient.
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